A phase I trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenously administered low-anticoagulant heparin (M6229) in critically ill sepsis patients

Background Histones released in response to cellular injury are important mediators of organ failure and death in sepsis. Preclinical studies demonstrate that neutralization of histones in sepsis is associated with improved outcome. M6229 is a low-anticoagulant heparin able to neutralize histones. W...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Intensive care medicine experimental Ročník 13; číslo 1; s. 84 - 15
Hlavní autori:	van Mourik, Niels, van Amstel, Rombout B. E., Slim, Marleen A., van Vught, Lonneke A., van der Poll, Tom, Huckriede, Joram, de Vries, Femke, de Kimpe, Sjef J., Crabbé, Raf, van Leeuwen, Simone J. M., Ekhart, Peter F., Reutelingsperger, Chris P. M., Nicolaes, Gerry A. F., Vlaar, Alexander P. J., Müller, Marcella C. A.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Cham Springer International Publishing 18.08.2025 Springer Nature B.V SpringerOpen
Predmet:	Anticoagulants Coronaviruses COVID-19 Critical Care Medicine Histones Human subjects Illnesses Intensive M6229 Medical research Medicine Medicine & Public Health Mortality Neutralization Patients Pharmacodynamics Pharmacokinetics Phase I Plasma Sepsis Septic shock Netherlands Phase I M6229 Histones Sepsis Septic shock Heparin Safety Pharmacokinetics Neutralization
ISSN:	2197-425X, 2197-425X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!